In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test

The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.